Achieving Scale in World’s Best Practice in Development in the Next 5-10 Years: What Would This Take?
Our CTO, Damon Rasheed, recently participated in a panel discussion at the BioConnections conference in Melbourne. The event brought together some of […]
May Events and Media Coverage
In the landscape of drug disMay has been a remarkable month for TrialKey, marked by high-profile events and significant media coverage that have greatly enhanced our visibility and strengthened our connections with key players in the industry. From participating in the Digital Health Festival and Pharma and Device Forum to making impactful presentations at Global Clinical Trials Connect, we've showcased how our AI technology is revolutionising clinical trials. Our media engagements, including features in the Herald Sun and Stockhead, and appearances on the Talking Healthtech and Eye on AI podcasts, have further solidified our leadership position. These activities have not only connected us with key decision-makers but also highlighted the growing interest and trust in TrialKey's innovative solutions. For our investors, these developments underscore our commitment to driving transformative change in the healthcare sector. Dive into our full blog to learn more about our journey and the exciting milestones we've achieved.
AI at the Helm of Clinical Trial Progress: TrialKey.ai Media and Event Coverage Highlights
In the landscape of drug discovery, AI-driven tools like TrialKey are revolutionizing clinical trial optimization, offering unparalleled accuracy rates exceeding 90%. By harnessing the power of AI and machine learning, TrialKey provides tailored recommendations to streamline trial design, execution, and understanding of drug mechanisms of action, ultimately reducing costs and saving time. This innovative approach accelerates medical research advancements, promising a future where breakthrough treatments reach patients faster and more efficiently.
Press Release: TrialKey Accurately Predicts Dimerix Phase 3 Trial Milestone Result
The recent positive results of the Dimerix (ASX: DXB) Phase 3 interim clinical trial have sparked a surge in share prices, proving the value of early insights. But here's the catch – TrialKey ASX: OPL) had already identified the potential success with a 74.51% probability before the official announcement!
2024 ANZ Clinical Trials: Industry Insights
Leveraging Predictive Technology for Enhanced Clinical Trial Outcomes: Insights into 2024 ANZ Clinical Trials Industry In the dynamic landscape of the Australia […]
Putting Patients First: How AI Enhances Clinical Trials and Patient Studies
In the ever-evolving landscape of healthcare, the patient’s voice is increasingly gaining prominence. As we strive for medical advancements, it becomes imperative […]
